SeaStar Medical Q3 revenue $0.2M, net loss $3.5M; QUELIMMUNE orders rising

SeaStar Medical Holding Corp

Net revenue $0.2M (Q3 2024: $0.1M); net loss $3.5M ($0.13/sh) vs $4.5M ($1.10/sh) a year ago.
Cash $13.8M at Sep 30, 2025, up from $1.8M at Dec 31, 2024; raised $12.4M in Q3 via equity and warrant exercise.
Three top children's hospitals adopted QUELIMMUNE; Q4 orders to date exceed full Q3 orders.
NEUTRALIZE-AKI trial interim analysis showed positive safety/efficacy signal; enrollment target raised to 339 patients (146 enrolled).
QUELIMMUNE SAVE registry shows 76% 60-day and 71% 90-day survival in 21 pediatric AKI patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.